Sydney, AUSTRALIA, September 28, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, will present at the investor conferences, as detailed below.
2021 Cantor Fitzgerald Global Virtual Healthcare Conference
Participants: Marc Voigt, CEO will present a presentation of the company in the form of a virtual event
Time Date: Wednesday, September 29, 2021 EDT (Eastern Daylight Time)
Goldman Sachs Small / Mid-Cap Health Day (virtual)
Presenter: An informal chat with Marc Voigt, CEO led by Goldman Sachs host Chris Cooper, Global Investment Research healthcare analyst and investor Q&A.
Deat: Thursday October 7, 2021, AEST (Australian Eastern Standard Time)
Immutep is a globally active biotechnology company, a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer and autoimmune diseases. Immutep is committed to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is an activator of antigen presenting cells (APC). first-class being studied in cancer and infectious diseases. Immutep is also developing a LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, including antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.
Further information can be found on the company’s website www.immutep.com or by contacting:
Australian Investors / Media:
Catherine Strong, Citadelle-MAGNUS
+61 (0) 406 759 268; [email protected]
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]